Hosted on MSN17m
Cambium jumps 43% as FDA approves Phase 3 trial for Elate OcularCambium Bio (ASX:CMB) has flagged approval from the U.S. FDA for phase three of a clinical trial using its Elate Ocular product to treat moderate to severe dry eye disease. The market clearly liked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback